Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins

Authors

Publication Details

Journal
PLoS ONE
Published
2026-03-09
DOI
https://doi.org/10.1371/journal.pone.0344592
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins

Deeba Shamim Jairajpuri, Tahani Bakhsh, Randa Mohammed Zaki, Mohammad Azhar Kamal et al.
PLoS ONE
Lung Cancer Treatments and Mutations
article

Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins

Deeba Shamim Jairajpuri, Tahani Bakhsh, Randa Mohammed Zaki, Mohammad Azhar Kamal, Hanadi M. Baeissa, Alaa Hamed Habib, Ghadir Sindi, Afnan Shakoori, Hadeel A. Alsufyani, Misbahuddin Rafeeq, Arwa Ishaq A. Khayyat
article en

Abstract

No abstract available for this paper.
PLoS ONEVol. 21(3)
Prince Sattam bin Abdulaziz University
Good health and well-being
Openalex Percentile: Top 28%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.